Abstract
We sought to determine whether circulating tumor cells in the blood stem cell harvest from patients with multiple myeloma are associated with a shortened disease-free survival. Prospective analysis was performed in 33 patients of blood obtained at leukapheresis for future transplantation. An immunofluorescence microscopy procedure identified the tumor cells by their morphology and monotypic light chain staining. Eighteen patients had increased (⩾0.2 × 106/l) monoclonal plasma cells circulating in the blood at stem cell harvest. Fifteen of the 18 have relapsed, with a median relapse-free survival of 6.2 months. Of 15 patients with <0.2 × 106 cells/l, seven have relapsed, with a median relapse-free survival of 22.5 months (P = 0.008). Patients with circulating plasma cells showed a trend toward shorter overall survival (P = 0.078). In a multivariate analysis using the bone marrow plasma cell labeling index and β2-microglobulin, the absolute number of plasma cells in the stem cell harvest achieved borderline significance for predicting relapse-free survival (P = 0.057). In conclusion, increased monoclonal plasma cells in the blood stem cell harvest are associated with a shortened relapse-free survival. This does not necessarily indicate that the circulating plasma cells were responsible for relapse. These results, however, have implications with regard to the timing of obtaining blood stem cells for patients who are candidates for ablative chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gertz, M., Witzig, T., Pineda, A. et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 19, 337–342 (1997). https://doi.org/10.1038/sj.bmt.1700670
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700670
Keywords
This article is cited by
-
Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
Annals of Hematology (2023)
-
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
Blood Cancer Journal (2023)
-
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era
Blood Cancer Journal (2016)
-
Reovirus as a successful ex vivo purging modality for multiple myeloma
Bone Marrow Transplantation (2014)
-
A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
Blood Cancer Journal (2011)